Virtual Event | September 13, 2023

Risk Reduction In mRNA Therapeutic Development

Source: Roche CustomBiotech

mRNA is at an inflection point. To reach its therapeutic potential in chronic, and even rare, disease applications, some biopharmaceutical manufacturing fundamentals must be addressed, including (but certainly not limited to):

  • The scale-up challenge, specifically the limitations of chromatography, must be solved to facilitate large volumes of homogenous supply.
  • Safety profiles must improve in lockstep with scale-up.
  • Immunogenicity must be optimized to specific disease states.
  • Raw materials quality and consistency standards must be established and adhered to.

Bioprocess Online Live hosted discussion on approaches to reducing mRNA therapeutic risk in parallel with increasing the scale of its production. We leaned into the expertise of leading technical minds in the space. Now available on-demand thanks to the support of Roche Custom Biotech.

access the Virtual Event!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Advancing RNA? Subscribe today.

Subscribe to Advancing RNA X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Advancing RNA